Biology Reference
In-Depth Information
10. Chan N, Bristow RG. "Contextual" synthetic lethality and/or
loss of heterozygosity: tumor hypoxia and modification of DNA
repair.
Clin Cancer Res
2010;16(18):4553
19. Guillet M, Boiteux S. Endogenous DNA abasic sites cause cell
death in the absence of Apn1, Apn2 and Rad1/Rad10 in.
Saccharomyces cerevisiae. EMBO J
2002;21(11):2833
41.
20. Chan KK, Zhang QM, Dianov GL. Base excision repair fidelity
in normal and cancer cells.
Mutagenesis
2006;21(3):173
e
60.
11. Ali M, Telfer BA, McCrudden C, et al. Vasoactivity of
AG014699, a clinically active small molecule inhibitor of pol-
y(ADP-ribose) polymerase: a contributory factor to chemo-
potentiation in vivo?
Clin Cancer Res
2009;15(19):6106
e
8.
21. Thompson LH, West MG. XRCC1 keeps DNA from getting
stranded.
Mutat Res
2000;459(1):1
e
18.
22. Neher TM, Shuck SC, Liu JY, Zhang JT, Turchi JJ. Identification
of novel small molecule inhibitors of the XPA protein using in
silico based screening.
ACS Chem Biol
2010;5(10):953
e
12.
12. Aziz K, Nowsheen S, Georgakilas AG. Nanotechnology in
cancer therapy: targeting the inhibition of key DNA repair
pathways.
Curr Mol Med
2010;10(7):626
e
65.
23. Shuck SC, Turchi JJ. Targeted inhibition of replication protein A
reveals cytotoxic activity, synergy with chemotherapeutic DNA-
damaging agents, and insight into cellular function.
Cancer Res
2010;70(8):3189
e
39.
e
13.
Iglehart JD, Silver DP. Synthetic lethality
a new direction in
cancer-drug development.
N Engl J Med
2009;361(2):189
e
91.
14. Ho AY, Atencio DP, Peters S, et al. Genetic predictors of adverse
radiotherapy effects: the Gene-PARE project.
Int J Radiat Oncol
Biol Phys
2006;65(3):646
e
98.
24. Shuck SC, Short EA, Turchi JJ. Eukaryotic nucleotide excision
repair: from understanding mechanisms to influencing biology.
Cell Res
2008;18(1):64
e
55.
15. Abbotts R, Madhusudan S. Human AP endonuclease 1 (APE1):
From mechanistic insights to druggable target in cancer.
Cancer
Treat Rev
2010;36(5):425
e
72.
25. Earley JN, Turchi JJ. Interrogation of nucleotide excision repair
capacity: impact on platinum-based cancer therapy.
Antioxid
Redox Signal
2011; 23 January [Epub ahead of print].
26. de Bono JS, Ashworth A. Translating cancer research into tar-
geted therapeutics.
Nature
2010;467(7315):543
e
35.
16. Plummer R. Perspective on the pipeline of drugs being devel-
oped with modulation of DNA damage as a target.
Clin Cancer
Res
2010;16(18):4527
e
e
9.
31.
17. Drew Y, Plummer R. The emerging potential of poly(ADP-
ribose) polymerase inhibitors in the treatment of breast cancer.
Curr Opin Obstet Gynecol
2010;22(1):67
e
27.
Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia
for prediction of response to therapy and cancer prognosis.
J Cell Mol Med
2010;14(1-2):18
29.
28. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two
modes of attack on the cancer cell widening the clinical appli-
cations.
Drug Resist Updat
2009;12(6):153
e
71.
18. Mitra S, Hazra TK, Roy R, et al. Complexities of DNA base
excision repair in mammalian cells.
Mol Cells
1997;7(3):305
e
12.
6.
e
e
